Pediatr Neurol. 2012 Dec;47(6):419-22. doi: 10.1016/j.pediatrneurol.2012.08.015.
Metabolic effects of aripiprazole and pimozide in children with tourette syndrome.
Source
Section of Child Neurology and Psychiatry, Department of Pediatrics, University of Catania, Catania, Italy.
Abstract
This study assessed the metabolic effects of aripiprazole and pimozide in pediatric
Tourette syndrome,
a neurodevelopmental condition characterized by multiple motor and
phonic tics. Patients receiving aripiprazole (n = 25) or pimozide (n =
25) were compared with medication-free patients (n = 25). Body mass
index, glycemia, triglyceridemia, and cholesterolemia were monitored at
baseline and 12 and 24 months after commencing treatment. The
aripiprazole group demonstrated significant increases in
cholesterolemia. The pimozide group demonstrated significant increases
in glycemia. Both groups demonstrated elevations in triglyceridemia not
significantly different from those in unmedicated control subjects. The
effect of aripiprazole on cholesterol was apparent after 12 months, but
leveled off during year 2 of treatment. Longitudinal studies are
required to evaluate the full extent of glycemic alterations with
pimozide. Both agents appear relatively safe for use in pediatric
Tourette syndrome. These findings will help guide medication selection in patients with specific medical vulnerabilities.
Nenhum comentário:
Postar um comentário